Patients suffering from severe allergic reactions now have access to a new, needle-free treatment option, as the US Food and Drug Administration (FDA) has approved neffy, a 2 mg epinephrine nasal spray developed by ARS Pharmaceuticals, Inc.
In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.
Yesterday (June 5) CluePoints, providers of established statistical and AI-driven software solutions, and the Food and Drug Administration (FDA) announced an extension to their long-standing collaboration.
Roquette, a global leader in plant-based ingredients and a key provider of pharmaceutical and nutraceutical excipients, announced today (May 14) the launch of its innovative Lycagel Flex hydroxypropyl pea starch premix for softgel capsules.
Sanofi, a global pharmaceutical giant, has announced a significant investment of over €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.
Yesterday (April 29), Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS).
LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries.
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.
Adults and children in the US with congenital thrombotic thrombocytopenic purpura (cTTP) can now access Adzynma for prophylactic and on-demand treatment.
It was announced today (October 31), that the US Food and Drug Administration (FDA) has granted permission to proceed with clinical investigations of small molecule treatment, roginolisib.
Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.
The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
Children in Europe living with HIV are on course to receive a once-daily treatment after EU marketing authorisation (EMA) was given to ViiV Healthcare’s Triumeq PD.
The Foundation for Sarcoidosis Research hosted more than 50 agency leaders in a session that addressed patient concerns in research, care, and diagnosis.
Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.
The company’s recent purchase by Drug Safety and Pharmacovigilance Services Solutions reportedly will fuel expansion of its Reportum PV platform technology.
A representative from the medication management solutions company suggests patient behavior data can be used to improve adherence to trial drug regimens.
Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.
Published by Tabula Rasa Healthcare, the report looks at the MedWise Risk Score, technology designed to determine ADE risk rising from medication regimens.
Two Chinese and one Korean over-the-counter (OTC) drugmakers have received US FDA warnings for violating good manufacturing practice (GMP) regulations for finished pharmaceuticals.
AstraZeneca says its hyperkalaemia candidate ZS-9 is back on track for approval after manufacturing issues at its Texas facility resulted in regulatory delays.
Kadam Exports Private has received a statement of non-compliance with GMP after the Danish Medicines Agency found manufacturing deficiencies at its facility in Gujarat.
Amneal Pharmaceuticals expects to bring production of some Impax Laboratories’ drugs in-house through a 100,000 sq. ft. expansion at its site in New York state.
Fresenius Kabi says drug ingredients made at an Indian plant hit with a US FDA warning letter meet quality specifications and has reiterated that tests were halted for technical reasons.
A piece of glass found in a vial of generic injectable product Pantoprazole Sodium has prompted AuroMedics Pharma to issue a nationwide voluntary recall.
Three-dimensional printing technology is attracting increased attention from the US FDA say Aprecia and Cycle, which have announced a partnership to develop 3D-printed orphan drugs.
